Drug Overview
Revefenacin (Theravance Biopharma/Mylan) is a long-acting muscarinic antagonist (LAMA) that will join a very crowded COPD market. The drug will be in direct competition with the gold-standard therapy Spiriva (tiotropium; Boehringer Ingelheim), as well as a host of other LAMA therapies that are available for the treatment of COPD. Revefenacin’s positive clinical trial data may help its uptake, but its late entry to the COPD market and its formulation as a nebulized therapy will significantly limit its potential.
Revefenacin (Theravance Biopharma/Mylan) is a long-acting muscarinic antagonist (LAMA) that will join a very crowded COPD market. The drug will be in direct competition with the gold-standard therapy Spiriva (tiotropium; Boehringer Ingelheim), as well as a host of other LAMA therapies that are available for the treatment of COPD. Revefenacin’s positive clinical trial data may help its uptake, but its late entry to the COPD market and its formulation as a nebulized therapy will significantly limit its potential.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
